The difference between HOTs and previous weight loss drugs and supplements is profound. Despite decades of development and hundreds of millions of prescriptions nothing in the weight loss space has ever triggered anything approaching the disruption we are seeing now.
Previous weight loss drugs worked primarily by suppressing appetite through stimulating the central nervous system (phentermine), blocking fat absorption in the gut (orlistat), or modulating mood and reward circuits (bupropion-naltrexone). These mechanisms produced modest results, with phentermine-topiramate achieving roughly 8% average body weight loss; orlistat, about 3%; bupropion-naltrexone, roughly 3%. These were marginal improvements with significant side effects including elevated heart rate, insomnia, anxiety, oily stools, fecal urgency and dependency risks. This is not including the long list of failed weight loss pharmaceuticals that caused serious illness, injury or death before being pulled from the shelves.
GLP-1 drugs achieve 15–22% average body weight loss with Retatrutide, still in trials, showing up to 28%. Far from an incremental improvement over prior drugs, it is a major leap into a different category of effectiveness, comparable to (and soon exceeding) bariatric surgery.
Previous weight loss drugs were blunt instruments that pushed on one lever (suppress appetite, block fat absorption, stimulate metabolism) and left the underlying biology unchanged. GLP-1s work by mimicking hormones that the body naturally produces, activating receptors throughout the brain, gut, pancreas, and cardiovascular system. They reduce food noise rather than simply making food less palatable or digestion less efficient. Users consistently describe this not as feeling sick or suppressed, but as simply not being hungry in the way they used to be. The term that has organically emerged is "liquid willpower."
Supplements occupy a different but equally important contrast. The weight loss supplement industry, which includes products like green tea extract, garcinia cambogia, raspberry ketones, conjugated linoleic acid, and hundreds of others. These are characterized by weak effect sizes (typically 1–2 kg over several months in the best-designed trials), high placebo response rates, inconsistent quality control, and a regulatory environment that permits marketing far in advance of scientific evidence. These are not even close to the same category of intervention as GLP-1 drugs.
Finally, and crucially, previous weight loss drugs produced weight loss only. GLP-1s produce weight loss plus cardiovascular improvement, addiction reduction, sleep apnea resolution, joint health benefits, and more. They are not just more effective weight loss drugs, they are a categorically different kind of medicine - Health Optimizer Therapies.
Explore the evidence...
Previous drugs achieved modest weight loss of 3–8% on average, with significant side effects and high relapse rates. GLP-1 drugs achieve 15–22% average weight loss, with retatrutide showing up to 28% in trials. This is not a categorically different level of effectiveness.
The weight loss industry was built on the premise that losing weight is hard and requires ongoing behavioral support, meal replacement products, coaching programs, and dietary supplements. HOTs have rendered that entire premise obsolete. WeightWatchers, after 62 years of operation and a peak market cap of over $6.5 billion, filed for bankruptcy in April 2025. Jenny Craig went out of business in 2023. These are the leading indicators of a full industry disruption driven by a technology that simply works better than everything that came before it.
Projected 20-Year Market Transformation from HOT Adoption
How quickly market change occurs.
Percentage of dieters that switch to HOTs.
Decline in diet programs, supplements, meal replacements, and bariatric surgery.
How large the new HOT-integrated industry becomes (Calibrate, Ro, Noom Med, etc.).
Impact on weight and health coaching services.
When the most rapid phase of change begins.
Projected 20-Year Change
-9.7%
-$8.3B annually
Total Market Size (USD)
Segment Breakdown (USD)
Traditional Dieting ($75B)
HOT-Based Programs ($5B)
Health Coaching ($5B)
Traditional Dieting ($75B) includes diet programs, products, meal replacements, supplements, and bariatric surgery—all facing obsolescence as HOTs prove vastly more effective. Weight Watchers' 2025 bankruptcy exemplifies this disruption. HOT-Based Programs ($5B currently) includes rapidly growing HOT-integrated platforms like Calibrate, Noom Med, Found, and telehealth prescribers like Ro and Hims & Hers. Health Coaching ($5B) faces uncertain demand—may decline as HOTs reduce need, or grow as the market expands to previously hopeless dieters.
Previous weight loss drugs produced weight loss only. GLP-1s produce weight loss plus cardiovascular improvement, addiction reduction, sleep apnea resolution, joint health benefits, and more.
We are entering a new era of healthcare based on a categorically different kind of medicine whose purpose is not just to save us from illness, but to help us be the best version of ourselves.
The next generation of HOTs will trigger a multi-trillion-dollar global disruption, affecting dozens of industries across multiple sectors, driving a radical global improvement in health and wellness encompassing at least 1 billion people worldwide before 2040.
Optimizing well with advanced HOTs will soon become as important as eating well with nutritious foods. Nations, industries, and individuals that recognize this early and act decisively will be best positioned to capture the extraordinary benefits of this transformation.
The information provided in this FAQ is for general informational and educational purposes only and is not intended to constitute medical advice, diagnosis, or treatment. This content does not establish a doctor-patient relationship. The content regarding GLP-1 receptor agonists (or any other medical treatments) should not be used as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay in seeking it because of something you have read here. The authors and publishers of this FAQ and related report make no representation or warranty, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information presented. Reliance on any information provided here is solely at your own risk.
